Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic Lupus erythematosus

Arthritis and Rheumatism

Volumn 43, Issue 8, 2000, Pages 1790-1800

  Llorente, Luis ^a   Richaud Patin, Yvonne ^a   García Padilla, Carlos ^a   Claret, Emmanuel ^b   Jakez Ocampo, Juan ^a   Cardiel, Mario H ^a   Alcocer Varela, Jorge ^a   Grangeot Keros, Liliane ^c   Alarcón Segovia, Donato ^a   Wijdenes, John ^b   Galanaud, Pierre ^c   Emilie, Dominique ^c  

^a Basic Sciences Department   (Mexico)

^b Diaclone   (France)

^c Institut Paris Sud sur les Cytokines   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; DAPSONE; INTERLEUKIN 10 ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; STEROID; THALIDOMIDE;

ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-10; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PILOT PROJECTS;

EID: 0033883903     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2     Document Type: Article

References (49)

1. Cytotoxic drugs
2. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration
3. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation
4. Novel approaches in the treatment of lupus nephritis
5. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus
6. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus: A potential mechanism of B lymphocyte hyperactivity and autoimmunity
7. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-γ-secreting cells in the peripheral blood
8. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus
9. Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins
10. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity
11. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus
12. Impaired production of IL-12 in systemic lupus erythematosus II. IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE
13. Role of interleukin 10 in the B-lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus
14. Interleukin 10 (IL-10) strongly reduces antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down regulation of class II major histocompatibility complex expression
15. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression
16. Interleukin-10 down-regulates MHC class II ab peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling
17. Interleukin-10 induces a long term antigen specific anergic state in human CD4+ T cells
18. Overview of cellular immune function in systemic lupus erythematosus
19. A randomized, controlled trial of IL-10 in humans: Inhibition of inflammatory cytokine production and immune responses
20. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers
21. 1 mice
22. Prognostic subsets and mortality in systemic lupus erythematosus
23. The 1982 revised criteria for the classification of systemic lupus erythematosus
24. Derivation of the SLEDAI: A disease activity index for lupus patients
25. Measurement of disease activity in systemic lupus erythematosus: Prospective validation of 3 clinical indices
26. Specificity and clinical relevance of antibodies to double-stranded DNA
27. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy: Towards a new methodology for measuring overall cytokine production in human in vivo
28. Diminished levels of T cell receptor ζ chains in peripheral blood T lymphocytes from patients with systemic lupus erythematosus
29. Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p62-RelA protein expression
30. Interleukin-10 promotes activation induced cell death of SLE lymphocytes mediated by Fas ligand
31. Th1/Th2 cytokines and T-cell death: Preventive effect of IL-12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from HIV-infected persons
32. A novel mouse with B cells but lacking serum antibody reveals an antibody independent role for B cells in murine lupus
33. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus
34. Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families
35. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
36. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia
37. Divergent effect of interleukin-10 on cytokine production by mononuclear phagocytes and endothelial cells
38. Contrasting effects of IL4, IL-10 and corticosteroids on RANTES production by human monocytes
39. Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts
40. Regulation of the production of the chemokine RANTES by endothelial cells: Synergistic induction by IFNgamma plus TNFalpha and inhibition by IL-4 and IL-13
41. IL-10 inhibits ICAM-1 expression on human Langerhans cells but not on keratinocytes, dermal endothelial cells or fibroblasts
42. Ultraviolet light and interleukin-10 modulate expression of cytokines by transformed human dermal microvascular endothelial cells (HMEC-1)
43. Involvement of cytokines, DNA damage, and reactive oxygen intermediates in ultraviolet radiation-induced modulation of intracellular adhesion molecule-1 expression
44. Interleukin-4 and interleukin-10 increase endotoxin stimulated human umbilical vein endothelial cell interleukin-8 release
45. Interleukin-10 induces E-selectin on small and large blood vessel endothelial cells
46. Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans
47. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts
48. Mechanism involved in the systemic suppression of antigen-presenting cell function by UV irradiation: Keratinocyte-derived IL-10 modulates antigen-presenting cell function of splenic adherent cells
49. Interleukin-10 production by cultured human keratinocytes: Regulation by ultraviolet B and ultraviolet A1 radiation